Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 2/2020

01-03-2020 | Antidepressant Drugs | Short Communication

Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model

Authors: Lijia Chang, Kai Zhang, Yaoyu Pu, Youge Qu, Si-ming Wang, Zhongwei Xiong, Yukihiko Shirayama, Kenji Hashimoto

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2020

Login to get access

Abstract

It is reported that dopamine D1 receptors in the medial prefrontal cortex play a role in the antidepressant actions of (R,S)-ketamine. However, its role in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, is unknown. In the locomotion test, tail suspension test, forced swimming test and 1% sucrose preference test, pretreatment with dopamine D1 receptor antagonist SCH-23390 did not block the antidepressant effects of (R)-ketamine in the susceptible mice after chronic social defeat stress. These findings suggest that dopamine D1 receptors may not play a major role in the antidepressant actions of (R)-ketamine.
Literature
1.
Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172(10):950–966CrossRef
2.
Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46(7):1459–1472CrossRef
3.
Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19(1):83–92CrossRef
4.
Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333(1):99–104CrossRef
5.
Fukumoto K, Toki H, Iijima M, Hashihayata T, J-i Yamaguchi, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 36(1):9–16CrossRef
6.
Zhang JC, Li SX, Hashimoto K (2014) R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141CrossRef
7.
Yang C, Shirayama Y, Jc Zhang, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632CrossRef
8.
Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry 82(5):e43–e44CrossRef
9.
Yang C, Qu Y, Fujita Y, Ren Q, Ma M, Dong C, Hashimoto K (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry 7(12):1294CrossRef
10.
Yang C, Ren Q, Qu Y, Zhang J-C, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin–independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18–28CrossRef
11.
Zhang K, Ma M, Dong C, Hashimoto K (2018) Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol 21(11):1025–1030PubMedPubMedCentral
12.
Hashimoto K (2016) Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46(11):2449–2451CrossRef
13.
Yang C, Han M, J-c Zhang, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283CrossRef
14.
Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267(2):173–176CrossRef
15.
Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K (2018) Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R, S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav 172:17–21CrossRef
16.
Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, Aghajanian GK, Duman RS (2015) Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions. Proc Nat Acad Sci USA 112(26):8106–8111CrossRef
17.
Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267(2):177–182CrossRef
18.
Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS (2019) Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun 10(1):223CrossRef
19.
Li Y, Zhu ZR, Ou BC, Wang YQ, Tan ZB, Deng CM, Gao YY, Tang M, So JH, Mu YL, Zhang LQ (2015) Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behav Brain Res 279:100–105CrossRef
20.
Hashimoto K, Shirayama Y (2018) What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine? Biol Psychiatry 84(1):e7–e8CrossRef
21.
Chang L, Toki H, Qu Y, Fujita Y, Mizuno-Yasuhira A, Yamaguchi JI, Chaki S, Hashimoto K (2018) No sex-specific differences in the acute antidepressant actions of (R)-ketamine in an inflammation model. Int J Neuropsychopharmacol 21(10):932–937CrossRef
22.
23.
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927CrossRef
24.
Ago Y, Tanabe W, Higuchi M, Tsukada S, Hashimoto K, Hashimoto H (2018) (R)-ketmaine, (S)-ketamine and their metabolites affect differentially in vivo monoamine release in the prefrontal cortex of mice: different involvement of AMPA receptor. Poster W-131 at 57th annual meeting of The American College of Neuropsychopharmacology, Hollywood, FL, 12 Dec 2018
Metadata
Title
Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model
Authors
Lijia Chang
Kai Zhang
Yaoyu Pu
Youge Qu
Si-ming Wang
Zhongwei Xiong
Yukihiko Shirayama
Kenji Hashimoto
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2020
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-019-01012-1

Other articles of this Issue 2/2020

European Archives of Psychiatry and Clinical Neuroscience 2/2020 Go to the issue

Original Paper

Predicting instructed simulation and dissimulation when screening for depressive symptoms

Original Paper

Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects

Original Paper

Higher BDNF plasma levels are associated with a normalization of memory dysfunctions during an antidepressant treatment

Original Paper

Longitudinal multi-level biomarker analysis of BDNF in major depression and bipolar disorder

Original Paper

Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury

Original Paper

Caudothalamic dysfunction in drug-free suicidally depressed patients: an MEG study